Related Experiment Video
Updated: Jun 10, 2026

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
Published on: March 11, 2016
Early biomarkers of renal injury
Dinna N Cruz1, Ching Yan Goh, Anja Haase-Fielitz
1Department of Nephrology, San Bortolo Hospital, Viale Rodolfi 37, 36100 Vicenza, Italy. dinnacruzmd@yahoo.com
Insights
Novel biomarkers for cardiorenal syndrome (CRS) can predict acute kidney injury (AKI) earlier than traditional markers. This allows for timely interventions, improving patient outcomes in heart and kidney conditions.
Area of Science:
- Nephrology
- Cardiology
- Biomarker Discovery
Background:
- Cardiorenal syndrome (CRS) involves heart and kidney interactions, leading to acute kidney injury (AKI) and high mortality.
- Current biomarkers like serum creatinine, urea, and diuresis delay AKI diagnosis by 24-48 hours.
- Common CRS scenarios include cardiac surgery, decompensated heart failure, and radiocontrast-induced nephropathy.
Purpose of the Study:
- To review novel renal biomarkers for predicting AKI in cardiorenal syndrome.
- To assess the clinical evidence and biologic characteristics of emerging AKI biomarkers.
- To explore the potential of these markers in extending the therapeutic window for patient management.
Main Methods:
- Literature review focusing on novel renal biomarkers.
- Evaluation of biomarkers including neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, interleukin 18, and fatty acid-binding proteins.
- Analysis of current clinical data in typical cardiorenal syndrome settings.
Main Results:
- Novel biomarkers show promise in predicting AKI.
- These markers indicate tubular injury, offering earlier detection than traditional methods.
- Specific biomarkers reviewed include NGAL, KIM-1, IL-18, and FABPs.
Conclusions:
- Novel renal biomarkers offer improved predictive ability for AKI in cardiorenal syndrome.
- Early AKI detection via these markers can facilitate timely and individualized patient management.
- These advancements may significantly improve outcomes for patients with cardiorenal interactions.
Abstract:
Cardiorenal syndrome (CRS) refers to pathophysiologic interaction of the heart and kidney and is associated with acute kidney injury (AKI) and high mortality. Cardiac surgery or acute decompensated heart failure and radiocontrast-induced nephropathy are common clinical scenarios of CRS. Unfortunately, established functional biomarkers of glomerular filtration rate such as serum creatinine, urea, and diuresis delay AKI diagnosis by 24 to 48 hours. Novel renal biomarkers indicating tubular injury are emerging and may have wide implications. This review focuses on several novel renal biomarkers with the most promising biologic characteristics and clinical evidence for their AKI predictive ability: neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, interleukin 18, and fatty acid-binding proteins. The value of each biomarker is reviewed on currently available clinical data in typical settings of CRS. These markers might extend the therapeutic window during which timely and individualized patient management might be possible.
Related Concept Videos
Serum Studies: Renal Function Tests
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Kidney Injury II: Pathophysiology
